Influence of oral adsorbent AST-120 on anticonvulsive effect of zonisamide in rats

[1]  眞汎 中野,et al.  球形吸着炭 (クレメジン原体) の吸着特性に関する検討 , 1997 .

[2]  S. Tange,et al.  Therapeutic Drug Monitoring in Pediatrics: A Need for Improvement , 1994, Journal of clinical pharmacology.

[3]  P. Walson.  Role of therapeutic drug monitoring (TDM) in pediatric anti-convulsant drug dosing , 1994, Brain and Development.

[4]  S. Iwakawa,et al.  Pharmacokinetics of zonisamide; saturable distribution into human and rat erythrocytes and into rat brain. , 1992, Journal of pharmacobio-dynamics.

[5]  S. Teraoka,et al.  Therapeutic effects of oral sorbent in undialyzed uremia. , 1988, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[6]  William J. Jusko,et al.  Berichten , 2005, Pharmaceutisch weekblad.

[7]  T. Sakai,et al.  [Clinical trial of oral adsorbent (AST-120) as conservative treatment in patient with chronic renal failure]. , 1985, Nihon Jinzo Gakkai shi.

[8]  J. Wagner,et al.  Pilot Study of Zonisamide (1,2‐Benzisoxazole‐3‐methanesulfonamide) in Patients with Refractory Partial Seizures , 1985, Epilepsia.

[9]  T. Karasawa,et al.  Differential antagonisms of anticonvulsants to various components of maximal seizures induced by electroshock or pentylenetetrazol in mice. , 1980, Journal of pharmacobio-dynamics.

[10]  T. Karasawa,et al.  3-Sulfamoylmethyl-1,2-benzisoxazole, a new type of anticonvulsant drug. Pharmacological profile. , 1980, Arzneimittel-Forschung.

[11]  B. Gallagher,et al.  Metabolism and anticonvulsant properties of primidone in the rat. , 1973, The Journal of pharmacology and experimental therapeutics.